Skip to search formSkip to main contentSkip to account menu

Mozobil

National Institutes of Health

Related topics

Related topics

4 relations
1.2 ML Plerixafor 20 MG/ML Injection [Mozobil]Plerixafor Injection [Mozobil]

Broader (2)

JM 3100Plerixafor

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
The interaction of Mozobil™ with carboxylates.
Mozobil(™) (1,1'-[1,4-phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane], 1, also known as JM3100 and AMD 3100) is a… 
2013
2013
A Higher Number of CD34+ Cells Collected during Mobilization Is Independently Associated with Successful Engraftment in Autologous Stem Cell Transplant Patients
Review
2010
Review
2010
FDA Review Summary: Mozobil in Combination with Granulocyte Colony-Stimulating Factor to Mobilize Hematopoietic Stem Cells to the Peripheral Blood for Collection and Subsequent Autologous…
Purpose: On December 15, 2008, the US Food and Drug Administration approved plerixafor (Mozobil®; Genzyme Corp.), a new small… 
Highly Cited
2010
Highly Cited
2010
Decreased Circulating Progenitor Cell Number and Failed Mechanisms of Stromal Cell-Derived Factor-1α Mediated Bone Marrow Mobilization Impair Diabetic Tissue Repair
OBJECTIVE Progenitor cells (PCs) contribute to postnatal neovascularization and tissue repair. Here, we explore the mechanism… 
Highly Cited
2009
Highly Cited
2009
Successful stem cell remobilization using plerixafor (mozobil) plus granulocyte colony-stimulating factor in patients with non-hodgkin lymphoma: results from the plerixafor NHL phase 3 study rescue…
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)